Fannin Receives CDMRP and Faris Foundation Grants to Advance Targeted RapDC Therapy for Ewing Sarcoma

HOUSTON, Aug. 14, 2026 /PRNewswire/ -- Fannin Partners, LLC today announced two new grants from the Congressionally Directed Medical Research Programs (CDMRP) and the Faris Foundation to advance development of a targeted Raptamer-Drug Conjugate (RapDC) therapy for Ewing sarcoma, an...